tirzepatide – Talk Bio

Eli Lilly Withdraws $1.9B Phase 2b Obesity Trial Before Launching Enrollment

2 weeks ago talkbio0Tagged bimagrumab, Clinical Trials, Diabetes Mellitus, Non-Insulin-Dependent, Eli, Eli Lilly, Obesity, regulatory strategy, tirzepatide, Trial Termination, Zepbound

Eli Lilly; obesity drug; tirzepatide; bimagrumab; trial termination; phase 2b; Zepbound; type 2 diabetes; clinical trial; regulatory strategy

ICER Draft Report: High-Cost GLP-1 Obesity Drugs Deemed Cost-Effective—Affordability Still a Concern

1 month ago talkbio0Tagged Affordability, cardiovascular benefits, Cost-Effectiveness, CREM gene, Glucagon-Like Peptide 1, Health Policy, Obesity, semaglutide, tirzepatide, value-based pricing

ICER; GLP-1; semaglutide; tirzepatide; obesity drugs; cost-effectiveness; health policy; affordability; value-based pricing; cardiovascular benefits

Diabetes and Obesity Drug Boom to Propel Lilly and Novo Nordisk to Pharma Sales Leadership by 2030: Evaluate

4 months ago talkbio0Tagged CagriSema, Diabetes, eli lilly, Evaluate report, Mounjaro, Nordisk, Obesity, Ozempic, Pharmaceutical Sales, semaglutide, tirzepatide, top-selling drugs, Wegovy, Zepbound

diabetes; obesity; pharmaceutical sales; Eli Lilly; Novo Nordisk; Evaluate report; top-selling drugs; tirzepatide; semaglutide; Mounjaro; Zepbound; Ozempic; Wegovy; CagriSema; 2030 forecast

Lilly says further head-to-head trial data back Zepbound over Novos Wegovy

5 months ago talkbio0Tagged Comparative Efficacy, Obesity, semaglutide, SURMOUNT-5 Trial, tirzepatide, Weight Loss

Tirzepatide, Semaglutide, Weight Loss, Obesity Treatment, SURMOUNT-5 Trial, Comparative Efficacy

Compounders just lost their case to put obesity drug tirzepatide back in shortage

5 months ago talkbio0Tagged Drug Shortage, Eli, Eli Lilly, Facilities Association, Glucagon-Like Peptide 1, Legal Case, Mounjaro, OFA, tirzepatide, United States Food and Drug Administration, Zepbound

Tirzepatide, compounding, FDA, drug shortage, Eli Lilly, Zepbound, Mounjaro, legal case, Outsourcing Facilities Association (OFA), GLP-1 medications

Eli Lilly’s Zepbound Receives FDA Approval as First Prescription Drug for Moderate-to-Severe Obstructive Sleep Apnea in Adults with Obesity

10 months ago talkbio0Tagged Approved, Glucagon-Like Peptide 1, Obesity, Sleep Apnea, Obstructive, tirzepatide, United States Food and Drug Administration, Zepbound

GLP-1, Obstructive Sleep Apnea (OSA), Obesity, Zepbound, Tirzepatide, FDA Approval, Sleep Disorder Treatment

FDA Reconsiders Tirzepatide Shortage Status, Allowing Continued Compounding

12 months ago talkbio0Tagged Drug Shortage, Glucagon-Like Peptide 1, Pharmacy facility, tirzepatide, United States Food and Drug Administration

Tirzepatide, FDA, drug shortage, compounding pharmacies, GLP-1 medications

FDA Reconsiders Removal of Eli Lilly’s Tirzepatide from Shortage List, Boosting Compounding Pharmacies

12 months ago talkbio0Tagged Compound, Diabetes Mellitus, Non-Insulin-Dependent, Eli, Eli Lilly, Glucagon-Like Peptide 1, Pharmacy facility, shortage, tirzepatide, United States Food and Drug Administration

FDA, Eli Lilly, Tirzepatide, GLP-1 drug, Shortage list, Compounding pharmacies, Weight loss medication, Type 2 diabetes treatment

Lilly’s Tirzepatide Clears Phase III Cardiovascular Study on Heels of Novo Nordisk’s Semaglutide

1 year ago talkbio0Tagged cardiovascular study, Eli Lilly, Nordisk, Obesity, Phase III, semaglutide, tirzepatide, Weight Loss

Tirzepatide, Lilly, Phase III, Cardiovascular Study, Novo Nordisk, Semaglutide, Heart Failure, Obesity, Weight Loss

Eli Lilly’s Tirzepatide Approved in China for Weight Loss Management Amid Growing Obesity Concerns

1 year ago talkbio0Tagged agonists, China, Diabetes, Eli, Eli Lilly, Glucagon-Like Peptide 1, Mounjaro, Nordisk, Obesity, semaglutide, tirzepatide, Wegovy, Weight Loss, Zepbound

Eli Lilly, Tirzepatide, Weight Loss, China, Obesity, Novo Nordisk, GLP-1 Agonists, Diabetes, Mounjaro, Zepbound, Semaglutide, Wegovy